Ribocure-B (06938) shares rose more than 9% during intraday trading. As of press time, the stock was up 4.45%, quoted at HK$52.85, with a turnover of HK$7.5983 million.
Ribocure-B announced that on October 16, 2026, the company entered into a share exchange agreement with minority shareholders. Under the terms and conditions of the agreement, the company has conditionally agreed to acquire, and the minority shareholders have separately and conditionally agreed to sell, the target shares, which together represent 49.71% of the total issued shares of the target company, resulting in the company holding full equity interest in the target company.
The target company, Ribocure Pharmaceuticals AB, is a clinical-stage biotechnology company organized under Swedish law in February 2022. As the company's international R&D center, the target company is primarily engaged in global clinical development and translational research of oligonucleotide therapeutics, with a particular focus on siRNA drugs targeting cardiovascular, metabolic, hepatic, renal and neurodegenerative diseases. The target company currently has five drug discovery and preclinical stage projects, two of which have advanced to near clinical filing stage, as well as two major out-licensing collaboration projects.
Comments